Postsynaptic $\alpha_1$- and $\alpha_2$-Adrenergic Receptors in Adrenergic Control of Capacitance Vessel Tone in Vivo

Dietmar Elsner, Duncan J. Stewart, Olaf Sommer, Jürgen Holtz, and Eberhard Basenge

SUMMARY The involvement of postsynaptic $\alpha_2$-adrenergic receptors in the adrenergic constriction of the capacitance vessels was studied in anesthetized, spontaneously breathing dogs under ganglionic blockade (hexamethonium, 10 mg/kg + 10 mg/kg/hr; methylatropine, 0.5 mg/kg). Effective vascular compliance was measured as an indicator of venous tone (blood volume was varied by ± 4 ml/kg in an 11-minute cycle of infusion, withdrawal, withdrawal, and reinfusion) and was calculated from the correlation between the observed changes in central venous pressure and the changes in blood volume. Sympathetic activity and central venous pressure were lower and effective vascular compliance was higher than values in untreated conscious dogs. The $\alpha_2$-agonist UK 14,304 (5-bromo-6-[imidazolin-2-ylamino]-quinoxaline; 0.04 and 0.12 $\mu$g/kg/min; $n = 6$) dose-dependently lowered compliance and increased central venous pressure to levels found in conscious dogs, as did the $\alpha_1$-agonist methoxamine (10 and 30 $\mu$g/kg; $n = 6$). Rauwolscine ($\alpha_2$-antagonist), 0.3 mg/kg, significantly attenuated the effects of UK 14,304, but not those of methoxamine, while prazosin ($\alpha_1$-antagonist), 0.12 mg/kg, attenuated the effects of methoxamine, but not those of UK 14,304 ($n = 6$ each). Under $\beta$-blockade (nadolol, 2 mg/kg; $n = 12$) venous tone was increased to about physiological levels by norepinephrine, 0.15 $\mu$g/kg/min i.v., or by neuronal norepinephrine release induced by tyramine, 10 $\mu$g/kg/min i.v. These increases were significantly attenuated by prazosin as well as by rauwolscine and were abolished by a combination of both. These results indicate that postsynaptic $\alpha_2$-adrenergic receptors (in addition to $\alpha_1$-adrenergic receptors) are functional in the venous system in vivo and contribute substantially to adrenergic sympathetic and humoral regulation of venous tone. (Hypertension 8: 1003-1014, 1986)

KEY WORDS • total effective vascular compliance • venous tone • vascular $\alpha_2$-adrenergic receptors • capacitance vessel constriction • rauwolscine • prazosin

ABNORMALITIES in venous function feature prominently in the pathophysiological changes found in various types of experimental hypertension as well as in hypertensive patients, and augmented venous tone is a key link underlying the postulated pathophysiological role of natriuretic hormone in hypertension. The abnormalities in venous function include increased sensitivity to norepinephrine, decreased venous distensibility, and decreased total vascular compliance. The decreased venous distensibility in borderline hypertensive patients has been shown to be due, at least in part, to increased $\alpha$-adrenergic vasoconstriction.

Postsynaptic vascular $\alpha$-adrenergic receptors are subdivided into $\alpha_1$-adrenergic receptors (the classic postsynaptic $\alpha$-adrenergic receptors) and the more recently recognized $\alpha_2$-adrenergic receptors. In various arterial beds in vivo, postsynaptic $\alpha_2$-adrenergic receptors mediate vasoconstriction induced by circulating and by neuronally released norepinephrine, in addition to vasoconstriction mediated by $\alpha_2$-adrenergic receptors and by other mechanisms. However, the role of postsynaptic $\alpha_2$-adrenergic receptors in the venous system in vivo is still unclear. Although this type of $\alpha$-adrenergic receptor contributes to adrenergic constriction of isolated veins in vitro,
Materials and Methods

Animals

Twelve mongrel dogs of either sex, weighing 19 to 47 kg (mean, 29 ± 6 kg), were used repeatedly (4–5 times) in different experimental protocols without repeating the same protocol in any dog. For each protocol, the dogs were anesthetized and acutely catheterized percutaneously, the catheters being removed at the end of the protocol. Intervals of at least 2 weeks were allowed between two consecutive experiments in each dog. The animals were fed a standard diet containing Na+, 2 to 4 mEq/kg/day, with free access to tap water. During the experimental period the dogs maintained their body weight and apparently remained in vigorous condition. In an additional two dogs, an inflatable occlusion cuff was implanted around the ascending aorta through a thoracotomy under pentobarbital anesthesia and sterile conditions. The dogs were allowed to recover for 2 weeks from the operation and then were used in similar protocols while under anesthesia (see Experimental Protocols). Seven anesthetized and acutely catheterized dogs underwent a laparotomy for removal of the spleen (3 dogs) or for application of occlusive snares around the arteries of the splanchnic bed (4 dogs). Following closure of the abdomen, these anesthetized dogs were used in protocols while under anesthesia (see Experimental Protocols). Seven anesthetized and acutely catheterized dogs underwent a laparotomy for removal of the spleen (3 dogs) or for application of occlusive snares around the arteries of the splanchnic bed (4 dogs). Following closure of the abdomen, these anesthetized dogs were used in protocols as will be described and were killed by an overdose of pentobarbital at the end of the protocol. All studies were performed in accordance with the guiding principles in the care and use of animals, as approved by the council of the American Physiological Society.

Experimental Preparation

For each of the experimental protocols, the dogs were anesthetized with pentobarbital, 27 ± 1 mg/kg plus 2.5 ± 0.5 mg/kg/hr i.v., and breathed spontaneously through an endotracheal tube. Arterial blood gases and pH were measured repeatedly throughout the experiment and kept within the physiological range (carbon dioxide tension, 35–41 mm Hg; oxygen tension, 78–90 mm Hg; pH, 7.36–7.44) by adjusting the infusion rate of anesthesia or by an i.v. infusion of 8.4% sodium bicarbonate, or both, if necessary. Body temperature was kept at 37.0 to 37.5°C by means of a heating pad.

Two peripheral venous lines were inserted for separate injection sites for drugs or i.v. infusions. The femoral artery was catheterized percutaneously for recording of arterial blood pressure and heart rate, for changing blood volume, and for arterial blood sampling. A catheter was placed into the right atrium under fluoroscopic control through the external jugular vein for recording of central venous pressure.

Ganglionic blockade (hexamethonium, 10 mg/kg + 10 mg/kg/hr; methylatropine, 0.5 mg/kg) and β-blockade (nadolol, 2 mg/kg) in Protocols 8 to 12 were administered, and the dogs received heparin, 500 U/kg initially and 250 U/kg/hr maintenance. Dextran (Macrodex®, 4 ml/kg, was exchanged for an equal volume of blood, which was stored in a waterbath at 37.0°C. Following an equilibration period of 45 minutes, the experimental protocols (see Table 1) were started. Saline and dextran were infused continuously during the experiments (2.5 and 1.5 ml/kg/hr in Protocols 1–6, respectively; 4 and 2.5 ml/kg/hr in Protocols 8–12, respectively, after an initial infusion of saline, 10 ml/kg, and dextran, 7 ml/kg).

Measurements

Arterial and venous pressures were measured with Statham P23 pressure transducers (Oxnard, CA, USA) and recorded continuously on a Watanabe Linear-corder (Herrsching, West Germany). Mean central venous pressure was recorded at a sensitivity of 0.17 mm Hg/mm (see Figure 1). Effective vascular compliance was measured as modified by Gauer and colleagues.21,22 The stored blood (4 ml/kg) was injected into the abdominal aorta through the femoral artery catheter at a rate of 2 ml/kg/min. After 1 minute the same volume of blood was withdrawn at the same rate, and after a further interval of 1 minute, another 4 ml/kg blood was withdrawn and, 1 minute thereafter, was rein infused in an identical fashion. Thus, the total cycle time was 11 minutes. From the central venous pressure tracings recorded during one such cycle of volume changes, 12 readings at 1-minute intervals (integrating central venous pressure over several respiratory cycles) were obtained according to Figure 1. For each cycle of volume changes a linear regression was calculated, relating the observed central venous pressure values to the induced changes in blood volume. The effective compliance of the total vascular bed was calculated as the inverse of the slope of this regression line (expressed in ml/mm Hg⁻¹·kg⁻¹). In experimental Protocols 1 and 2, cardiac output was measured 10 minutes before every compliance measurement using the dye dilution technique (indocyanine green).

For estimation of norepinephrine release rate, a tracer amount of [3H]norepinephrine was infused intravenously at a rate of 0.5 µCi/min and arterial blood samples were taken at 10-minute intervals. Plasma norepinephrine concentration was quantified by a radioenzymatic technique.23 [3H]Norepinephrine was separated from its metabolites by column chromatography,24 and specific activity was estimated by liquid scintillation spectrometry. The release rate of endogenous norepinephrine into the plasma24 is calculated as ([3H]norepinephrine infusion rate × steady state plasma norepinephrine)/steady state plasma [3H]norepinephrine.
Experimental Protocols
The 12 dogs without the aortic cuff were assigned to 10 experimental protocols as follows (Table 1). Each dog was used once in control experiments with selective α-agonists (Protocols 1 or 2), once in experiments under α₁-blockade by prazosin (Protocols 3 or 4), and once in experiments under α₂-blockade by rauwolscine (Protocols 5 or 6). Seven of these dogs were used in experiments analyzing the effects of changes in intravascular volume (Protocol 7), and each dog was used once in experiments under β-blockade (Protocols 8–10). During each of the experimental conditions listed in Table 1, a cycle of volume changes for analyses of compliance was performed. Additionally, in Protocols 1 and 2, cardiac output was measured before starting the cycle.

The α-adrenergic blockers (Protocols 3–6, 9, 10, and 12) were applied 15 minutes before the compliance measurements were made. The cycle was started 5 minutes after the application of α-agonists. In pilot experiments, rather constant venous and arterial pressure levels were observed following bolus injections of methoxamine for at least 20 minutes, while continuous infusions of UK 14,304, norepinephrine, and tyramine had to be applied for steady state conditions over such a period of time.

After control measurements in Protocol 7, mean central venous pressure was elevated by an infusion of dextran (approximately 50 ml/kg) above those pressure values observed with the highest doses of α-agonists in protocols 1 through 6, and compliance was measured in this state. Then, blood was withdrawn in at least four steps to lower central venous pressure again, and compliance measurements were repeated at each step (i.e., at 4 different basal central venous pressure values with the last one being lower than the lowest pressure value observed in Protocols 1–6).

The dosages of norepinephrine and tyramine (Protocols 8–10, 12) were adjusted according to pilot experiments to yield a decline in effective vascular compliance to at least comparable to that obtained with the higher dosages of the selective α-agonists in Protocols 1 through 6. When the measurements during norepinephrine or tyramine infusions were finished, the infusions were discontinued and intervals of 15 to 20 minutes were necessary for central venous pressure and arterial pressure to return to baseline values. The protocols then were continued.

Protocols 1 through 6 lasted 90 minutes, Protocol 7 lasted 2 hours, and Protocols 8 to 12 lasted 3 hours. After the end of the experimental protocols, all drug infusions were stopped, protamine was given, the catheters were removed, and the animals were allowed to recover (except following Protocol 12; see below).

In three of the 12 dogs two further protocols were studied. With the dogs under pentobarbital anesthesia and ganglionic blockade as already described, plasma norepinephrine concentration and norepinephrine release rate were measured under control conditions for 60 minutes and for a further 60 minutes after the administration of prazosin, 0.12 mg/kg, or rauwolscine, 0.3 mg/kg, respectively.

In the two dogs with chronically implanted pneumatic cuffs around the ascending aorta, experiments (Protocol 11) were performed with the dog under pentobarbital anesthesia, ganglionic blockade, and β-blockade as already described. A second arterial catheter introduced through the femoral artery was placed proximal to the cuff for pressure measurements. After control measurements of compliance, proximal systolic pressure was elevated by inflating the occlusion cuff in a stepwise fashion with increasing volumes, and we repeated the measurements at each obtained level of proximal systolic pressure. The maximal pressure value obtained in this manner was higher than the systolic pressure reached with the highest doses of agonists in the other protocols. Following deflation of the cuff, norepinephrine (0.15 µg/kg/min) was infused and compliance was measured again.

In Protocol 12, the dogs had occlusive snares around the truncus celcius and the superior and inferior mesenteric arteries. Following compliance measurement under ganglionic and β-blockades, the splanchnic arteries were occluded and compliance was measured 3 minutes later. After 15 minutes of splanchnic occlusion, the snares were released and the splanchnic bed was reperfused; 20 minutes later, basal compliance was measured again. Thereafter, the protocol was executed as listed in Table 1, and arterial blood samples were withdrawn for plasma catecholamine measurement at each step of the protocol. In the three splenectomized dogs, the effects of UK 14,304 (0.12 µg/kg/min), methoxamine (30 µg/kg), and norepinephrine (0.15 µg/kg/min) in the presence of nadolol (2 mg/kg) were studied; thereafter, these dogs were killed by an overdose of pentobarbital.

Calculations and Drugs Used
Mean values ± SEM are presented. For comparison between treatment and control groups (Protocols 1–6) we used Student’s t test for unpaired data; for comparison between treatment and control data in Protocols 8 to 10 and 12 we applied Student’s t test for paired data with Bonferroni’s correction according to the number of comparisons.

The following drugs and solutions were used (dosages refer to the bases of the salts): pentobarbital sodium (Ceva, Bad Segeberg, West Germany), hexamethonium bromide (Sigma, München, West Germany), methylatropine bromide (E. Merck AG, Darmstadt, West Germany), nadolol (Von Heyden, Regensburg, West Germany), heparin sodium (Hoffmann-La Roche, Grenzach-Wyhlen, West Germany), prazosin HCI (Pfizer, Karlsruhe, West Germany), rauwolscine HCI (Roth, Karlsruhe, West Germany), methoxamine HCI (Wellcome, London, England), UK 14,304 (Pfizer, Sandwich, England), indocyanine green (Paesel, Frankfurt, West Germany), 1-norepinephrine HCI (Hoechst, Frankfurt, West Germany), tyramine chloride (E. Merck AG, Darmstadt), protamine HCI (Hoffmann-La Roche, Grenzach-Wyhlen), 8.4% sodium bicarbonate (Delta-Pharma, Pfäffingen, West Germany), dextran 60 (Macrodex; Schiwa, Glandorf, West Germany).
TABLE 1. Experimental Protocols

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Methoxamine, 10 μg/kg</th>
<th>Methoxamine, 30 μg/kg</th>
<th>Methoxamine, 100 μg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>α₁-blockade: prazosin, 0.12 mg/kg</td>
<td>Methoxamine, 10 μg/kg</td>
<td>Methoxamine, 100 μg/kg</td>
</tr>
<tr>
<td>2</td>
<td>UK 14,304, 0.04 μg/kg/min</td>
<td>UK 14,304, 0.04 μg/kg/min</td>
<td>Methoxamine, 30 μg/kg</td>
<td>Methoxamine, 30 μg/kg</td>
</tr>
</tbody>
</table>

Results

Selective α-Agonists and Effective Vascular Compliance (Protocols 1–6)

Typical tracings of phasic and mean central venous pressure during cycles of volume changes are depicted in Figure 1. Under control conditions (ganglionic blockade), a slope of 0.22 mm Hg·kg·ml⁻¹ was obtained, yielding an effective vascular compliance (i.e., the inverse of the slope) of 4.55 ml·mm Hg⁻¹·kg⁻¹. During UK 14,304 (0.12 μg/kg/min) administration, central venous pressure was elevated, the amplitude of the changes in central venous pressure during the cycle of volume changes was larger, and consequently, the slope was augmented to 0.47 mm Hg·kg·ml⁻¹, yielding an effective vascular compliance of 2.13 ml·mm Hg⁻¹·kg⁻¹.

The basal hemodynamic parameters in Protocols 1 to 6 before the application of α-agonists are summarized in Table 2. Under ganglionic blockade, effective vascular compliance was higher and central venous pressure was lower than those in untreated conscious dogs. Basal data during prazosin (Protocols 3 and 4) were not different from those in control Protocols 1 and 2. With rauwolscine, a higher mean arterial pressure (p<0.05) and slightly higher central venous pressure

---

**Figure 1.** Effects of volume alterations (ΔV) on central venous pressure (CVP) under control conditions and during an infusion of UK 14,304 (0.12 μg/kg/min) in a dog used in Protocol 2. (After starting the infusion of UK 14,304, pressure zero was shifted downward to center the tracing). Arrows indicate sequence of values obtained during the cycle of volume changes. Highly significant correlations between central venous pressure values and volume variations were obtained (r = 0.95 and r = 0.99, respectively).
**Table 1. (continued)**

<table>
<thead>
<tr>
<th>7 (n = 7)</th>
<th>8 (n = 4)</th>
<th>9 (n = 4)</th>
<th>10 (n = 4)</th>
<th>11 (n = 4)</th>
<th>12 (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>β-blockade: nadolol, 2 mg/kg</td>
<td>β-blockade: nadolol, 2 mg/kg</td>
<td>β-blockade: nadolol, 2 mg/kg</td>
<td>β-blockade: nadolol, 2 mg/kg</td>
<td>β-blockade: nadolol, 2 mg/kg</td>
</tr>
<tr>
<td>Stepwise variation of intravascular volume</td>
<td>Norepinephrine, 0.15 μg/kg/min</td>
<td>Norepinephrine, 0.15 μg/kg/min</td>
<td>Norepinephrine, 0.15 μg/kg/min</td>
<td>Stepwise variation of aortic obstruction</td>
<td>Temporary splanchnic arterial occlusion and reperfusion</td>
</tr>
<tr>
<td>Tyramine, 10 μg/kg/min</td>
<td>Tyramine, 10 μg/kg/min</td>
<td>Tyramine, 10 μg/kg/min</td>
<td>Tyramine, 10 μg/kg/min</td>
<td>Tyramine, 10 μg/kg/min</td>
<td></td>
</tr>
<tr>
<td>Prazosin, 0.12 mg/kg</td>
<td>Rauwolscine, 0.3 mg/kg</td>
<td>Norepinephrine, 0.015 μg/kg/min</td>
<td>Norepinephrine, 0.15 μg/kg/min</td>
<td>Prazosin, 0.12 mg/kg, + rauwolscine, 0.3 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2. Baseline Hemodynamic Data in Protocols 1 Through 6**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Ganglionic blockade</th>
<th>Ganglionic blockade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1 and 2)</td>
<td>(3 and 4)</td>
</tr>
<tr>
<td></td>
<td>+ prazosin (5 and 6)</td>
<td>+ rauwolscine</td>
</tr>
<tr>
<td>MAP (mm Hg)</td>
<td>96±5</td>
<td>96±4</td>
</tr>
<tr>
<td>HR (beats/min)</td>
<td>116±5</td>
<td>114±6</td>
</tr>
<tr>
<td>CVP (mm Hg)</td>
<td>-0.3±0.2</td>
<td>-0.2±0.2</td>
</tr>
<tr>
<td>EVC (ml·mm Hg⁻¹·kg⁻¹)</td>
<td>5.0±0.5</td>
<td>5.3±0.5</td>
</tr>
</tbody>
</table>

Values are means ± SEM. MAP = mean arterial pressure; HR = heart rate; CVP = central venous pressure; EVC = effective vascular compliance.

*P < 0.05, compared with control values.

(not significant) were observed, while effective vascular compliance tended to be lower (not significant) than that in the control Protocols 1 and 2).

In experiments without α-blockers (Protocols 1 and 2), the α₁-selective agonist methoxamine dose-dependently augmented mean arterial pressure and total peripheral resistance without affecting heart rate, and only a slight, but not significant, decrease in cardiac output was observed at the highest agonist dose (Protocol 1; Table 3). Similar changes were observed with the α₁-selective agonist UK 14,304 (Protocol 2; see Table 3).

The effects of the two selective α-agonists on the capacitance vessels are summarized in Figures 2 and 3. To clarify the demonstration of constrictive agonist effects, data of the slope of the pressure-volume relationship (i.e., the effective vascular stiffness) are presented. The α₁-agonist methoxamine (10 and 30 μg/kg) dose-dependently reduced effective vascular compliance, thus increasing effective vascular stiffness by 0.06 ± 0.03 and 0.24 ± 0.03 mm Hg·kg·ml⁻¹, and increased central venous pressure by 0.53 ± 0.10 and 1.74 ± 0.25 mm Hg. Rauwolscine, 0.3 mg/kg, did not significantly modify these effects, although basal values of central venous pressure and effective vascular stiffness during rauwolscine were slightly higher.

Prazosin, 0.12 mg/kg, significantly attenuated the methoxamine-induced increases in effective vascular stiffness and central venous pressure (see Figure 2).

The α₁-agonist UK 14,304 (0.04 and 0.12 μg/kg/...
Effects of methoxamine on effective vascular stiffness (EVS) and central venous pressure (CVP) under control conditions (Protocol 1), after prazosin (0.12 mg/kg; Protocol 3) and after rauwolscine (0.3 mg/kg; Protocol 5). Asterisks indicate significant difference (p < 0.01) between values during prazosin infusion and under control conditions.

Mean arterial pressure was increased by 9 ± 2 and 30 ± 6 mm Hg by the two dosages of methoxamine. This increase was not modified by rauwolscine but was significantly attenuated by prazosin (see Figure 3). Rauwolscine significantly attenuated this effect (increase of only 2 ± 1  and 8 ± 2 mm Hg), but prazosin did not.

Changes in Volume and Afterload

In seven dogs under ganglionic blockade central venous pressure was elevated by an infusion of dextran, 50 ml/kg, to a level of 1.8 ± 0.2 mm Hg, yielding an effective vascular stiffness of 0.29 ± 0.02 mm Hg·kg·ml⁻¹, and increased central venous pressure by 0.72 ± 0.16 and 1.31 ± 0.20 mm Hg. These effects were not modified by prazosin but were significantly attenuated by rauwolscine (see Figure 3). Mean arterial pressure was increased by 9 ± 2 and 30 ± 6 mm Hg by the two dosages of methoxamine. This increase was not modified by rauwolscine but was significantly attenuated by prazosin (increase of only 2 ± 3 and 5 ± 5 mm Hg). The two doses of UK 14,304 increased mean arterial pressure by 15 ± 4 and 36 ± 7 mm Hg. Rauwolscine significantly attenuated this effect (increase of only 2 ± 1 and 8 ± 2 mm Hg), but prazosin did not.

Effects of changes in intravascular volume (reflected by changes in central venous pressure, CVP) on effective vascular stiffness (EVS). Data of EVS and CVP obtained in experimental Protocols 1 and 2 with selective α-agonists are added for comparison, demonstrating that the effects on the capacitance vessels induced by the high doses of α-agonists cannot be explained by secondary increases in intravascular volume.

Reabsorption ratio). It should be noted that the increase in effective vascular stiffness induced by the higher concentration of agonists was used for pharmacological characterizations (see Figures 2 and 3).

In four experiments in two dogs with chronically...
implanted aortic occlusion cuffs effective vascular stiffness was not significantly altered by increasing the degree of aortic obstruction, thus obtaining different levels of proximal systolic pressure, but was significantly augmented by norepinephrine infusion (0.15 μg/kg/min; Table 4).

Effect of Norepinephrine and Tyramine on Effective Vascular Stiffness

The effects of norepinephrine and tyramine on effective vascular stiffness under β-blockade were studied in 12 dogs in Protocols 8 to 10 and in the four dogs used in Protocol 12, after volume infusion of dextran, 10 ml/kg, and saline, 10 ml/kg, to obtain a basal central venous pressure above 0.3 mm Hg (i.e., in a range where effective vascular stiffness is independent of increasing central venous pressure; see Figure 4). The effects of norepinephrine and tyramine on hemodynamics and on capacitance vessels in Protocols 8 through 10 are summarized in Table 5. The doses chosen augmented effective vascular stiffness and central venous pressure to levels found in untreated conscious dogs.10 The arterial plasma levels of norepinephrine measured during infusion of tyramine (10 μg/kg/min) and norepinephrine (0.015 and 0.15 μg/kg/min) in dogs under ganglionic and β-blockade (Protocol 12) are depicted in Figure 5 together with the hemodynamic data of this protocol. The tyramine-induced elevation of circulating norepinephrine cannot have contributed to the effects of tyramine on venous tone, as is shown by a comparison with the effects of norepinephrine, 0.015 μg/kg/min, in this protocol. Arterial plasma epinephrine concentration under ganglionic and β-blockade was 22 ± 7 pg/ml and did not change throughout this protocol.

The effects on capacitance vessels induced by norepinephrine (0.15 μg/kg/min) were attenuated significantly by both rauwolscine (0.3 mg/kg) and prazosin (0.12 mg/kg), but not by sham treatment (10 ml saline; Figure 6). Similarly, the effects of tyramine (10 μg/kg/min) on capacitance vessels were significantly attenuated by rauwolscine as well as by prazosin, but not by sham treatment (Figure 7). Following combined application of rauwolscine and prazosin (Protocol 12), the effects of tyramine (10 μg/kg/min) and of norepinephrine (0.15 μg/kg/min) on effective vascular stiffness and on venous pressure were abolished.

The elevation of mean arterial pressure induced by norepinephrine (0.15 μg/kg/min) was attenuated by prazosin to 52 ± 3% of the control response (Protocol 9) and by rauwolscine to 56 ± 6% (Protocol 10). It was abolished by the combination of prazosin and rauwolscine (Protocol 12) but was not significantly attenuated by sham treatment (Protocol 8). Similarly, the tyra-

### Table 4. Effective Vascular Stiffness and Increases in Afterload (Protocol 11, n = 4)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control</th>
<th>Cuff</th>
<th>Cuff</th>
<th>Cuff</th>
<th>Cuff</th>
<th>Norepinephrine, 0.15 μg/kg/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proximal systolic pressure (mm Hg)</td>
<td>120 ± 4</td>
<td>140 ± 2*</td>
<td>154 ± 2*</td>
<td>171 ± 1*</td>
<td>184 ± 2*</td>
<td>180 ± 1*</td>
</tr>
<tr>
<td>EVS (mm Hg·kg·min⁻¹)</td>
<td>0.47 ± 0.02</td>
<td>0.42 ± 0.03</td>
<td>0.44 ± 0.03</td>
<td>0.48 ± 0.03</td>
<td>0.48 ± 0.08</td>
<td>0.61 ± 0.05*</td>
</tr>
</tbody>
</table>

Values are means ± SEM. EVS = effective vascular stiffness. *p < 0.01, compared with control values.

### Table 5. Cardiovascular Effects of Norepinephrine and Tyramine (Protocols 8–10; n = 12)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Norepinephrine, 0.15 μg/kg/min</th>
<th>Tyramine, 10 μg/kg/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP (mm Hg)</td>
<td>98 ± 2</td>
<td>157 ± 6*</td>
</tr>
<tr>
<td>HR (beats/min)</td>
<td>116 ± 8</td>
<td>117 ± 8</td>
</tr>
<tr>
<td>CVP (mm Hg)</td>
<td>0.6 ± 0.1</td>
<td>3.4 ± 0.4*</td>
</tr>
<tr>
<td>EVC (ml·mm Hg·kg⁻¹·min⁻¹)</td>
<td>4.9 ± 0.3</td>
<td>1.9 ± 0.1*</td>
</tr>
</tbody>
</table>

Values are means ± SEM. MAP = mean arterial pressure; HR = heart rate; CVP = central venous pressure; EVC = effective vascular compliance. *p < 0.001, compared with control values.

### Figure 5. Effects of i.v. tyramine and norepinephrine infusions on effective vascular stiffness (EVS), central venous pressure (CVP), arterial plasma norepinephrine (NE), and mean arterial pressure (MAP) in four dogs under ganglionic and β-blockade (Protocol 12). Columns are shown in the sequence in which the measurements were performed: open columns indicate basal conditions. The tyramine-induced augmentation of circulating norepinephrine cannot account for the concomitant increase in venous tone.
mine-induced elevation was attenuated by prazosin to 50 ± 9% and by rauwolscine to 64 ± 14%; it was abolished by the combination of the antagonists and was not affected by sham treatment.

Basal values of mean arterial pressure, central venous pressure, and effective vascular stiffness tended to increase following rauwolscine, but the changes did not reach the level of significance. Following sham treatment, prazosin, or the combination of prazosin and rauwolscine, these basal levels remained unchanged or tended to decline.

Norepinephrine Release Rate

In six experiments in three dogs under ganglionic blockade, plasma norepinephrine concentration was 75 ± 27 pg/ml and norepinephrine release rate amounted to 2.8 ± 0.2 ng/kg/min. This level is approximately 18% of the release rate measured in conscious dogs at rest (O. Sommer, unpublished observations). Prazosin (0.12 mg/kg) did not significantly modify plasma norepinephrine concentration (from 96 ± 56 to 104 ± 31 pg/ml) or norepinephrine release rate (from 3.2 ± 0.4 to 3.5 ± 0.7 ng/kg/min; n = 3). After application of α2-blockade by rauwolscine, plasma norepinephrine concentration initially increased from 53 ± 2 to 113 ± 45 pg/ml and norepinephrine release rate increased from 2.5 ± 0.2 to 5.9 ± 1.8 ng/kg/min (data obtained 20 minutes after injection of antagonist), but both parameters returned to baseline values within 30 minutes (52 ± 19 pg/ml and 2.3 ± 0.8 ng/kg/min, respectively).

Effect of Temporary Splanchnic Arterial Occlusion on Effective Vascular Stiffness

In the dogs under ganglionic and β-blockade (Protocol 12), occlusion of the truncus celiaus and the superior and inferior mesenteric arteries immediately augmented mean arterial pressure (from 101 ± 7 to 133 ± 7 mm Hg; p < 0.001) and central venous pressure (from 1.7 ± 0.5 to 3.5 ± 0.9 mm Hg; p < 0.05), while effective vascular stiffness was only slightly modified (from 0.27 ± 0.02 to 0.31 ± 0.03 mm Hg·kg·ml−1; not significant). This occlusion-induced increase in effective vascular stiffness amounted to 15 ± 7% of the increase induced by norepinephrine in these dogs later in the protocol and to 15 ± 9% of the increase induced by tyramine. Following 15 minutes of splanchic arterial occlusion, a transient hypotension was observed with the onset of splanchic reperfusion, and preclosure hemodynamic values again were reached 4 to 12 minutes thereafter. It should be noted that later during Protocol 12, constrictive responses of the venous and arterial systems to norepinephrine and tyramine were observed similar to those observed in Protocols 8 to 10 in dogs that were not subjected to temporary occlusion.

Effective Vascular Stiffness in Splenectomized Dogs

In three splenectomized dogs under ganglionic blockade, the pressor effects of the agonists on the venous and the arterial systems were comparable in magnitude to the effects observed in normal dogs under ganglionic blockade. Administration of UK 14,304 (0.12 µg/kg/min) augmented effective vascular stiffness (from 0.28 ± 0.04 to 0.50 ± 0.01 mm Hg·kg·ml−1; p < 0.05), central venous pressure (from 1.9 ± 0.2 to 3.5 ± 0.2 mm Hg; p < 0.001), and mean arterial pressure (from 101 ± 7 to 145 ± 11 mm Hg; p < 0.01). The respective augmentations induced by methoxamine (30 µg/kg) were from 0.30 ± 0.04 to 0.49 ± 0.01 mm Hg·kg·ml−1 (p < 0.05), from 1.8 ± 0.1 to 2.7 ± 0.1 mm Hg (p < 0.01), and from 111 ± 9 to 156 ± 6 mm Hg (p < 0.05). Those induced
Thus, the slope of the pressure-volume relation should have been altered within only a small range (±4 ml/kg). and allowing enough time for mixing) and the volume change caused by splenic contraction do not substantially modify the measured effective vascular stiffness; see Figure 4). In the experiments with selective α-agonists were slightly below 0 mm Hg, we cannot exclude a secondary volume effect accounting in part for the observed increase in stiffness induced by the low doses of α-agonists. However, such an effect can be excluded for the high doses of α-agonists on which pharmacological characterizations are based. These doses were applied when central venous pressure values were well above 0 mm Hg (i.e., in a range where changes in intravascular volume and central venous pressure, respectively, do not significantly influence effective vascular stiffness; see Figure 4). In the experiments in which norepinephrine and tyramine were used, volume was infused to obtain central venous pressure values well above 0 mm Hg before starting the protocol, thus minimizing any potential secondary volume effects on measured vascular stiffness. Furthermore, the similarity of the responses between splenectomized and normal dogs indicates that volume changes caused by splenic contraction do not substantially modify the measured effective vascular stiffness.

All agonists substantially increased mean arterial pressure (see Tables 3 and 5) and thereby cardiac afterload. The αα-agonist clonidine is reported to depress ventricular function at high load. It could be argued that this effect would induce some degree of functional cardiac failure, increasing central venous pressure. Thus, as a result of marked afterload dependency, cardiac output would vary inversely with the cycle of volume alterations, thereby amplifying the actual changes in central venous pressure. However, there are strong arguments against this hypothesis. First, the...
α-agonists did not significantly decrease cardiac output (see Table 3). Second, the increased central venous pressure values during administration of α-agonists were always well within the normal range found in conscious dogs and were not in a range consistent with cardiac failure. Third, in experiments similar to the ones presented, which were performed in dogs equipped with chronic aortic flowmeters, cardiac output never changed inversely with the cycle of volume changes, neither under control conditions nor during an infusion of norepinephrine, 0.15 μg/kg/min. Fourth, in the dogs with chronically implanted aortic occlusion cuffs, effective vascular stiffness was not affected by increases in proximal systolic pressure of a greater magnitude than those caused by the α-agonists (see Table 4). Therefore, significant changes in effective vascular stiffness caused by agonist-induced increases in afterload (i.e., independent of venoconstriction cuffs, effective vascular stiffness was not affected by increases in proximal systolic pressure of a greater magnitude than those caused by the α-agonists (see Table 4). Therefore, significant changes in effective vascular stiffness caused by agonist-induced increases in afterload can be excluded for our experimental conditions.

Another factor to be considered is the redistribution of blood flow. Theoretically, one of the α-agonists used in our study could preferentially constrict arterioles in the splanchnic bed, thereby distributing blood flow away from a compartment with a high compliance and slow regional venous return to a compartment with a low compliance and fast return. The measured total effective vascular compliance would thereby decrease without any real change in capacitance vessel tone. In the resistance vessels of the splanchnic bed, the α1-type of adrenergic receptor seems to predominate. The α1-agonist methoxamine does not redistribute blood flow away from compartments with slow venous return in dogs, but such redistribution cannot be excluded for α2-agonists. However, a mechanically induced complete redistribution of flow away from the splanchnic bed only marginally (i.e., 15% of the agonist response) affected effective vascular compliance. Thus, it is very unlikely that in our experiments an agonist-induced redistribution of blood flow away from the splanchnic bed accounted for the observed decrease in total effective vascular compliance.

From this critique of the model we conclude that the observed changes in effective vascular compliance (or stiffness) reflect, under our experimental conditions, mainly changes in capacitance vessel tone.

**Pharmacological Characterization of α-Adrenergic Receptors in Capacitance Vessels**

The α1-agonist methoxamine dose-dependently increased effective vascular stiffness and central venous pressure, establishing venoconstriction. These effects are mediated by α1-adrenergic receptors, as they were not affected by the selective α1-antagonist rauwolscine but were significantly attenuated by the selective α2-antagonist prazosin (see Figure 2). The α2-agonist UK 14,304 increased effective vascular stiffness and central venous pressure in a dose-dependent manner to a similar degree as did methoxamine. These effects were not affected by α1-blockade but were significantly attenuated by α2-blockade. Therefore, the UK 14,304-induced constriction of the capacitance vessels is characterized as being mediated by α2-adrenergic receptors (see Figure 3). The two doses of the selective α-agonists were chosen to yield equivalent arteriolar effects (i.e., similar increases in mean arterial pressure and total peripheral resistance; see Table 3). At equipotent doses with respect to arterioles, both selective α-agonists also yield equivalent effects on the low pressure system (see Figures 2 and 3), with the higher agonist doses increasing effective vascular stiffness and central venous pressure to about physiological levels. The tendency of a rauwolscine-induced arterial and venous vasoconstriction (though not significant in all protocols) might have resulted from a central sympathectomy that is not completely suppressed by the ganglionic blockade. This interpretation is supported by the lack of such a pressor effect of rauwolscine in anesthetized dogs with spinal transection and by the transient augmentation of the norepinephrine release rate observed in the present study. However, this pressor effect was too small relative to the effects induced by the agonists to confound the antagonism at the vascular level.

We conclude that functional postsynaptic α2-adrenergic receptors, in addition to postsynaptic α1-adrenergic receptors, exist in the venous system of the intact dog and mediate constriction of the capacitance vessels induced by selective α-agonists. This conclusion is in agreement with findings in the pithed rat in vivo and with a number of in vitro studies on veins. In contrast to our results, however, it was postulated that the "postsynaptic α2-adrenoceptors were not functional in the capacitance vessels of the dog." These authors drew their conclusion from a lack of effect of the α2-agonist BHT-933 (azelpepoxide) on cardiac output in spinalized dogs under ganglionic blockade. Although this approach might yield only indirect and vague information on venous tone, it is unclear why they did not observe an increase in central venous pressure during BHT-933 infusion as we did during UK 14,304 infusion. The breed of dogs might explain some of the differences, as only beagles were used in their study. The number of postsynaptic α2-adrenergic receptors and/or the contractile responsiveness to their activation seem to vary with age, temperature, endothelial influences, and levels of blood pressure (and perhaps also with race) to a greater extent than that of α2-adrenergic receptors.

**Adrenergic Control of Capacitance Vessels**

The finding of functional postsynaptic α2-adrenergic receptors in the venous system of our model does not yet allow any conclusion on the relative number of either α-adrenergic receptor subtype in the venous system nor does it answer the question of whether there is a preferentially innervated, intrasympathetic α1-adrenergic receptor and a preferentially humoral, extrasynaptic α2-adrenergic receptor, as has been proposed, but not confirmed, for the arterial system.

In our model under β-blockade, i.v. infusion of norepinephrine increased effective vascular stiffness and central venous pressure to about physiological lev-


\[ \alpha_2 \text{-ADRENERGIC CONTROL OF VENOUS TONE IN VIVO/Elsner} \]

els, as did tyramine. These increases were significantly attenuated by prazosin and by rauwolscine, but not by sham treatment (see Figures 6 and 7). The combination of both antagonists abolished the increases induced by tyramine or by norepinephrine. These results demonstrate that both circulating and neurally released norepinephrine constrict capacitance vessels in vivo by summing \( \alpha_2 \)-adrenergic and \( \alpha_1 \)-adrenergic receptor mediated components of contractile activation.14 Although the mechanisms by which tyramine and sympathetic stimulation induce neuronal release of norepinephrine are not identical, this is not likely to make a difference regarding the access to and activation of postsynaptic \( \alpha \)-adrenergic receptors. We conclude that postsynaptic \( \alpha_2 \)-adrenergic receptors are intrasynaptically located and therefore innervated in the venous system of the dog. Thus, the hypothesis of preferentially innervated vascular \( \alpha_2 \)-adrenergic, and preferentially humoral \( \alpha_1 \)-adrenergic receptors is again not confirmed.

Based on in vitro studies, a predominance of postsynaptic \( \alpha_2 \)-adrenergic receptors in human veins has been postulated.18,43 These findings, together with the results from our study, indicate that also in humans postsynaptic \( \alpha_2 \)-adrenergic (in addition to \( \alpha_1 \)-adrenergic) receptors contribute substantially to the adrenergic sympathetic and humoral regulation of capacitance vessel tone. This would complement the role of this receptor type in the control of arteriolar tone in humans13 and extend the evidence that sympathetic and humoral adrenergic activation act on two types of vascular \( \alpha \)-adrenergic receptors, of which one (the vascular \( \alpha_2 \)-adrenergic receptor) seems to be preferentially modulated by various physiological and pathophysiological factors.

Venous tone in hypertensive patients and in models of experimental hypertension is augmented.1,4,7 This augmentation is considered one of the causal factors for the release of the endogenous inhibitor of \( Na^+ \) K+-ATPase in low renin hypertension.5,44 The enhanced \( \alpha_2 \)-adrenergic receptor responsiveness of arteries in hypertension.46 and the involvement of \( \alpha_2 \)-adrenergic receptors in sympathetic venuconstriction (indicated in our model) raise the following questions: Is augmented venous \( \alpha_2 \)-mediated constriction the mechanism of the altered venous tone in hypertension? Is a preferential action of calcium antagonists on such an \( \alpha_1 \)-mediated venoconstriction involved in the prevention or correction of hypertension and in the normalization of associated abnormalities in blood cell sodium transport and in plasma proteins45,46 by those drugs? The extreme heterogeneity of vascular smooth muscle should prevent conclusions from analogy; however, these questions deserve investigation.

In conclusion, our study demonstrates that in dogs the tone of the entire capacitance vasculature in vivo can be augmented by activation of postsynaptic \( \alpha_2 \)-adrenergic receptors as well as of \( \alpha_1 \)-adrenergic receptors. Furthermore, circulating and neurogenic norepinephrine constrict the capacitance vasculature through activation of both \( \alpha \)-adrenergic receptor subtypes. This constriction augments right ventricular filling pressure and venous tone within the ranges observed in the healthy, conscious dog at rest. Thus, activation of postsynaptic venous \( \alpha_2 \)-adrenergic receptors might be involved in the physiological regulation of central venous pressure by the sympathetic nervous system.

Acknowledgments

We are indebted to Roland Busath for careful technical assistance. Prazosin was generously supplied by Pfizer (Karlsruhe, West Germany), UK 14-304 by Pfizer (Sandwich, England), dextran 60 (Macrodex) by Schiwa (Glandorf, West Germany), and nadolol by Von Heyden (Regensburg, West Germany).

References

9. McGrath JC. Evidence for more than one type of postsynaptic \( \alpha \)-adrenoceptor. Biochem Pharmacol 1982;31:467–484
11. Elsner D, Saed M, Sommer O, Holtz J, Bassenge E. Sympathetic vasoconstrictive sensitivity to \( \alpha_2 \)-adrenoceptor blockade: no evidence for preferential innervation of \( \alpha_2 \)-adrenergic receptors in the canine femoral bed. Hypertension 1984;6:915–925
41. Medgett IC, Hicks PE, Langer SZ. Smooth muscle α2-adrenoceptors mediate vasoconstrictor responses to exogenous norepinephrine and to sympathetic stimulation to a greater extent in spontaneously hypertensive than in Wistar Kyoto rat tail arteries. J Pharmacol Exp Ther 1984;231:159–165
44. De Wardener HE, Clarkson EM. Concept of natriuretic hormone. Physiol Rev 1985;65:638–758
Postsynaptic alpha 1- and alpha 2-adrenergic receptors in adrenergic control of capacitance vessel tone in vivo.

D Elsner, D J Stewart, O Sommer, J Holtz and E Bassenge

*Hypertension*. 1986;8:1003-1014
doi: 10.1161/01.HYP.8.11.1003

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1986 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/8/11/1003

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Hypertension* is online at:
http://hyper.ahajournals.org//subscriptions/